Durata Therapeutics

Last updated
Durata Therapeutics, Inc.
Industry Pharmaceutical industry
Founded2009;16 years ago (2009)
DefunctNovember 17, 2014;10 years ago (2014-11-17)
FateAcquired by Actavis (now Allergan)
Headquarters Morristown, New Jersey

Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million.

History

On December 21, 2009, the company acquired Vicuron Pharmaceuticals and its drug candidate, dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer and commenced operations. [1]

On April 19, 2011, the company initiated Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections. [2]

In 2012, the company moved its global headquarters from Morristown to Chicago and received $2 million in tax credits. [3]

References

  1. ↑ "Newly Formed Durata Therapeutics Acquires Pfizer's Vicuron Subsidiary" (Press release). PR Newswire. December 21, 2009.
  2. ↑ "Durata Therapeutics Initiates Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections" (Press release). Business Wire. April 19, 2011.
  3. ↑ Frost, Peter (November 14, 2012). "Durata biotech moving headquarters to Chicago". Chicago Tribune .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.